No abstract

No abstract

This educational activity discusses several medications that are in phase III clinical trials and have not been approved by the FDA for treatment or management of multiple sclerosis at the time of publication. This list of medications includes cladribine, dimethyl fumarate, fingolimod, laquinimod, teriflunomide, fampridine, alemtuzumab, daclizumab, and rituximab. AcknowledgementsThe authors wish to thank Frank L. Urbano, MD, FACP, of PRIME ® for his assistance with the development of this publication. Alexandria, VA 22314; 703.683.8416; 703.683.8417 (fax F a c u l t y Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. 6. Seek and publish content that does not duplicate content in the Journal of Managed Care Pharmacy. 7. Subject all supplements to expert peer review. S1 Introduction S3 Results of Educational Needs Assessment S3 Immunopathology of MS S4 Diagnosis of MS S4 Clinically Isolated Syndrome S5 Is the Current Definition of CIS Adequate? S6 Imaging Modalities in MS S7 Treatment of Patients with CIS: Overview of Clinical Trials S8 Key Implications of Clinical Trials for Managed Care Pharmacists S9 Emerging Therapies for MS S9 Oral Agents S12 Monoclonal Antibodies S12 Key Implications of Emerging Therapies for Managed Care Pharmacists S13 Summary S16 Continuing Education: CE/CME Submission Instructions and Posttest QuestionsTarget Audience This activity is intended for managed care pharmacists and managed care physicians. This is an application-based learning activity. Learning ObjectivesUpon completion of this program, participants will be able to:1. Evaluate data submitted by managed care pharmacists pertaining to current pharmacy practice trends in multiple sclerosis (MS) management.2. Assess newest evidence in MS diagnosis and treatment impacting pharmacy practice.3. Identify paradigm shifts in MS treatment and management and the rapidly evolving role of the managed care pharmacist. Funding and Original Presentation of This Learning ActivityThis supplement was sponsored by P...

Coronary heart disease (CHD) persists as a major cause of morbidity and mortality in the United States, with more than 40% of all deaths each year directly attributed to the disease. Dyslipidemia is recognized as a major risk factor for the development and progression of CHD, with clinical trials clearly demonstrating the public health and economic benefits of favorable cholesterol modification. As a result of this evidence, the National Cholesterol Education Program (NCEP) has developed guidelines for the detection, evaluation, and treatment of high blood cholesterol in adults. The most recent of the NCEP recommendations, the Adult Treatment Panel III (ATP III) guidelines, were released in May 2001 and build on the earlier editions and reiterate the importance of low-density lipoprotein cholesterol (LDL-C) reduction to modify CHD risk. New features of the guidelines include the identification of CHD risk equivalents; lower treatment target goals; an emphasis on conditions conferring a higher risk for CHD, such as the metabolic syndrome; and a scoring system for calculating CHD risk. The ATP III emphasis on risk assessment will result in a substantial increase in the number of patients considered at risk for CHD and will expand the number eligible for lifestyle and drug intervention.

No abstract